DB3, LLC (FKA THE DASCHLE GROUP)

Lobbying for OTSUKA AMERICA PHARMACEUTICAL, INC · Pharmaceutical manufacturer

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Research, development, and reimbursement of novel serotonergic agonists for mental health conditions

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.